Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$70.27 USD

70.27
5,424,803

+1.80 (2.63%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $70.26 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ABIOMED (ABMD) Earnings Beat, Revenues Miss Estimates in Q2

by Zacks Equity Research

Impella's solid show in Japan drives ABIOMED's (ABMD) fiscal second-quarter results.

QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View

by Zacks Equity Research

We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.

Masimo (MASI) Earnings Beat Estimates in Q3, View Raised

by Zacks Equity Research

Masimo (MASI) raises its 2019 product revenue guidance.

Urmimala Biswas headshot

Impressive Near-Term Outlook for Medical Instruments Industry

by Urmimala Biswas

Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.

Chemed (CHE) Q3 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Chemed (CHE) witnesses balanced segmental growth in third-quarter 2019.

McKesson (MCK) Q2 Earnings Meet Estimates, Revenues Beat

by Zacks Equity Research

McKesson's (MCK) Q2 results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty, and Medical-Surgical Solutions.

Fresenius Medical (FMS) Q3 Earnings & Revenues Top Estimates

by Zacks Equity Research

Fresenius Medical's (FMS) Q3 earnings benefit from strong segmental performance and solid 2019 EPS outlook.

Stryker (SYK) Q3 Earnings Meet Estimates, Revenues Beat

by Zacks Equity Research

Stryker's (SYK) Q3 earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.

Has Edwards Lifesciences (EW) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (EW) Outperforming Other Medical Stocks This Year?

Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q1

by Zacks Equity Research

We are upbeat about the year-over-year uptick in both Coronary and peripheral device revenues within Cardiovascular Systems' (CSII) domestic market.

Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained

by Zacks Equity Research

Accuray (ARAY) reiterates revenue and adjusted EBITDA view for fiscal 2020.

Ecolab (ECL) Earnings and Revenues Miss Estimates in Q3

by Zacks Equity Research

Global Industrial unit aid Ecolab's (ECL) Q3 results; 2019 EPS view slashed.

Walgreens Boots (WBA) Q4 Earnings Surpass, Margins Fall

by Zacks Equity Research

Growth within the Retail Pharmacy USA and Pharmaceutical Wholesale divisions of Walgreens Boots (WBA) is partially offset by a dull performance at Retail Pharmacy International.

TMO vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

TMO vs. EW: Which Stock Is the Better Value Option?

3 Reasons Why Edwards Lifesciences (EW) Is a Great Growth Stock

by Zacks Equity Research

Edwards Lifesciences (EW) could produce exceptional returns because of its solid growth attributes.

Edwards Lifesciences (EW) Beats on Q3 Earnings, Ups EPS View

by Zacks Equity Research

Edwards Lifesciences (EW) reports strong Q3 sales on the recent FDA indication expansion of SAPIEN 3 and SAPIEN 3 Ultra systems.

McKesson (MCK) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

McKesson's (MCK) Pharmaceutical and Specialty Solutions unit is expected to have driven its fiscal Q2 results.

Edwards Lifesciences (EW) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 15.57% and 5.52%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Panel Of Zacks Experts headshot

Navigating The Healthcare Industry: Science Fiction Turns to Reality

by Panel Of Zacks Experts

Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!

Can Global Industrial Unit Drive Ecolab's (ECL) Q3 Earnings?

by Zacks Equity Research

Positive developments in the Global Industrial unit are expected to have driven Ecolab's (ECL) Q3 results.

Medical Products' Earnings Roster for Oct 23: TMO, BSX & More

by Zacks Equity Research

Encouraging growth in the emerging markets despite the ongoing trade tiff is likely to contribute to revenues in the medical products space this earnings season.

Should You Buy Edwards Lifesciences (EW) Ahead of Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cerner (CERN) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Top-line growth, expected increase in bookings and solid show by Population Health, Revenue Cycle and IT Works are anticipated to get reflected in Cerner's (CERN) Q3 earnings.

What's in the Offing for Baxter's (BAX) Earnings in Q3?

by Zacks Equity Research

Baxter's (BAX) Q3 earnings is likely to have benefited from better-than-expected performance at Acute Therapies segment, solid product portfolio and anticipated rise in revenues.

What's in Store for Varian Medical (VAR) in Q4 Earnings?

by Zacks Equity Research

Varian (VAR) is expected to have gained from core Proton Therapy platform in fiscal Q4.